Skip to main content

Table 4 Univariate predictors of 30 day mortality in patients with CAL and HAL.a

From: Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: A Danish historical cohort study

 

CAL

 

HAL b

 

Predictor variables by category

Odds ratio (95% CI)

P-value

Odds ratio (95% CI)

P-value

Variables known at the time of patient presentation

    

Demographics

    

Age > 65 years

3.9 (1.9-8.1)

<0.001*

0.7 (0.2-2.0)

0.46

Case associated with travelling to another country

0.4 (0.1-0.9)

0.03*

x

x

Comorbid illnesses

    

Any comorbidityc

2.4 (1.1-4.9)

0.02*

2.2 (0.2-21.5)

0.49

Immunosuppression

6.3 (2.7-14.8)

<0.001*

1.5 (0.5-4.6)

0.48

Malignancy

4.7 (1.6-13.9)

0.005*

2.1 (0.7-6.9)

0.20

Renal insufficiency

7.2 (1.4-37.1)

0.02

0.4 (0.04-3.4)

0.38

Charlson Comorbidity Index ≥ 2

3.7 (1.7-8.3)

0.001*

1.5 (0.5-4.6)

0.48

Current smoker

0.5 (0.2-1.1)

0.09

0.4 (0.1-1.6)

0.21

Symptoms

    

Self-reported fever

0.4 (0.2-0.9)

0.03*

2.1 (0.7-6.6)

0.21

Dyspnoea

2.4 (1.1-5.1)

0.03*

0.6 (0.2-1.9)

0.42

Headache

0.1 (0.01-0.5)

0.01*

0.4 (0.05-4.3)

0.49

Confusion

1.9 (0.9-4.2)

0.01*

0.3 (0.03-2.5)

0.26

Signs

    

Normal pulmonary stethoscopy

0.2 (0.1-1.02)

0.05

1.6 (0.3-8.4)

0.56

Laboratory tests

    

Lymphocytosis, lymphocyte count >3.5 cells 109/L

6.7 (0.9-49.6)

0.06

2.6 (0.1-45.4)

0.52

Bilirubin >23 mikromol/L

8.3 (2.9-24.1)

<0.001*

1.0 (0.3-4.1)

0.96

Creatinine >115 mikromol/L

2.5 (1.2-5.2)

0.01*

0.7 (0.2-2.6)

0.57

Blood urea nitrogen >7.5 mmol/L

4.2 (1.3-13.3)

0.02*

0.9 (1.1-5.6)

0.89

Hyponatremia, sodium <128 mmol/L

0.3 (0.1-1.0)

0.049*

0.6 (0.1-2.6)

0.49

Hypercapnia, PaCO2 >6 kPa

4.4 (0.97-19.9)

0.06

1.6 (0.3-10.1)

0.60

Atrial fibrillation at admission

2.6 (1.01-6.9)

0.048*

1.2 (0.3-5.1)

0.77

X-ray findings

    

Unilateral infiltrate on chest x-ray

0.8 (0.4-1.6)

0.46

0.4 (0.1-1.2)

0.09

Severity of illness

    

PSI risk class >2

9.1 (2.1-38.7)

<0.01*

2.2 (0.7-2.7)

0.20

CURB65 risk class >2

3.6 (1.0-12.8)

0.045*

0.6 (0.1-6.3)

0.68

Variables known later during admission

    

Treatment for legionellosis

    

Treatment with anti-legionella antibiotics

    

<24 hours from baselined

1 (ref.)

 

1 (ref.)

 

>24 hours from baselined

3.6 (0.8-15.6)

0.09

0.4 (0.1-2.0)

0.24

No treatment with anti-legionella antibiotics during admission

11.5 (2.1-64.3)

<0.01*

6.0 (0.4-85.2)

0.19

  1. a For community-acquired cases 30 days from admission. For hospital-acquired cases 30 days from onset of symptoms
  2. b A case was defined as hospital-acquired if the patient had been admitted within the preceding 10 days or if the patient developed
  3. symptoms of legionellosis more than 2 days after hospital admission.
  4. c Immunosuppression, malignancy, chronic obstructive pulmonary disease, ischaemic heart disease, congestive heart failure, diabetes mellitus
  5. or renal insufficiency.
  6. d For community-acquired cases time from admission. For hospital-acquired cases time from beginning of symptoms.
  7. * P-level < 0.05 is considered statistically significant